Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Since the discovery of the anticancer potential of ruthenium-based complexes, several species were reported as promising candidates for the treatment of breast cancer, which accounts for the greatest number of new cases in women every year worldwide. Among these ruthenium complexes, species containing bioactive ligand(s) have attracted increasing attention due to their potential multitargeting properties, leading to anticancer drug candidates with a broader range of cellular targets/modes of action. This review of the literature aims at providing an overview of the rationally designed ruthenium-based complexes that have been reported to date for which ligands were carefully selected for the treatment of hormone receptor positive breast cancers (estrogen receptor (ER+) or progesterone receptor (PR+)). In addition, this brief survey highlights some of the most successful examples of ruthenium complexes reported for the treatment of triple negative breast cancer (TNBC), a highly aggressive type of cancer, regardless of if their ligands are known to have the ability to achieve a specific biological function.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024301 | PMC |
| http://dx.doi.org/10.3390/molecules25020265 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MgRu.
IUCrdata
August 2025
State Key Laboratory of Metastable Materials Science and Technology Yanshan University,Qinhuangdao 066004 People's Republic of China.
A cubic phase with composition MgRu (tetra-tetra-contamagnesium hepta-ruthenium) was obtained during high-pressure sinter-ing of a mixture with an initial chemical composition of MgRuB. MgRu has space-group symmetry 43 and adopts the Mg Pt type of structure, which is categorized as one of the two structural types identified in complex compounds.
View Article and Find Full Text PDFPlatinum-group metal half-sandwich complexes of sugar-isoxazol(in)e conjugates - synthesis and evaluation of their antineoplastic and antimicrobial activities.
Eur J Pharm Sci
September 2025
Department of Organic Chemistry, University of Debrecen, P.O. Box 400, H-4002 Debrecen, Hungary. Electronic address:
Platinum-group metal half-sandwich complexes are considered to be potential replacements of the clinically widely used platins which have several side effects and tend to cause resistance to develop. In our previous works, we used a range of 2-pyridyl-substituted N- and C-glycosyl heterocycles as N,N-chelating ligands to prepare ruthenium(II), osmium(II), iridium(III) and rhodium(III) polyhapto arene/arenyl half-sandwich complexes. Some of these complexes, particularly with the C-glucopyranosyl isoxazole derived ligand in its O-perbenzoylated form, exhibited greater anticancer efficiency than cisplatin and had minimal or negligible effects on non-transformed fibroblasts.
View Article and Find Full Text PDFCu/Ru Relay Catalysis Enables Functionalization of Allenic Alcohols with Stereodivergence and Skeleton Diversity.
J Am Chem Soc
August 2025
Hubei Research Center of Fundamental Science-Chemistry, College of Chemistry and Molecular Sciences, Wuhan University, Wuhan 430072, China.
The stereodivergent synthesis of structurally complex molecules bearing multiple stereochemical elements represents a pivotal challenge in modern synthetic chemistry, particularly for bioactive compounds, where stereochemical nuances dictate pharmacological profiles. While stereodivergent dual catalysis has advanced full access to stereoisomers with stereogenic centers, the integration of stereodefined alkenes into chiral molecules with both stereochemical and skeletal diversification remains elusive. In this study, we report stereo- and skeleton-divergent access to chiral fluorinated -heterocycles with comprehensive stereocontrol of [(,), (,), (,), (,)] and [(,), (,), (,), (,)] enabled by a bimetallic Cu/Ru relay catalytic system, featuring redox-neutral efficiency and atom/step economy.
View Article and Find Full Text PDFCyclometalating Ligand Affords NIR Absorption in Ruthenium Complexes for Type-I Photodynamic Therapy.
Angew Chem Int Ed Engl
August 2025
State Key Laboratory of Fine Chemicals, Frontiers Science Center for Smart Materials Oriented Chemical Engineering, Dalian University of Technology, Dalian, 116024, China.
The development of NIR photosensitizers (PSs) based on Ru complexes with Type-I process holds substantial promise for photodynamic therapy (PDT) of cancer, though this breakthrough remains unrealized to date. Herein, a pair of cyclometalated Ru enantiomers, [Λ/Δ-Ru-dqpy-TPABP]Cl (dqpy: 2,6-di(quinolin-2-yl)pyridine; TPABP: 4-(4-(pyridine-2-yl)-2,1,3-benzothiadiazol-7-yl)triphenylamine) (Λ/Δ-Ru-TPABP), were synthesized and evaluated. These complexes exhibit strong Ru(d) and TPABP(π) → dqpy(π*) charge transfer ((metal and ligand)-ligand charge transfer; ML-LCT) absorption at ∼640 nm, with an extended absorption tail reaching up to 800 nm.
View Article and Find Full Text PDFPyridyl-Thiourea Ruthenium and Osmium Complexes: Coordination of Ligand and Application as FLP Hydrogenation Catalysts.
Molecules
August 2025
Instituto de Síntesis Química y Catálisis Homogénea (ISQCH), CSIC-Universidad de Zaragoza, Departamento de Química Inorgánica, Pedro Cerbuna 12, 50009 Zaragoza, Spain.
Pyridyl-thiourea complexes of formula [(Cym)MCl(κ,-)][SbF] (Cym = --MeCHPr; = -(-tolyl)--(2-pyridylmethyl)thiourea); M = Ru (), Os ()) were synthesized by reacting the corresponding metal dimers [{(Cym)MCl}(-Cl)] with in the presence of NaSbF. Subsequent chloride abstraction with AgSbF, followed by NH deprotonation using NaHCO, afforded the cationic complexes [(Cym)M(κ,,)][SbF] (M = Ru (), (); M = Os ()) and [(Cym)M(κ,)][SbF] (M = Ru (); M = Os ()). The proposed structures for the prepared compounds are based on NMR data.
View Article and Find Full Text PDF